Eularis Releases First-Ever Study on ROI of Pre-Launch Named Patient Programmes

NEW YORK, N.Y. and LONDON, U.K., Sept. 16 (SEND2PRESS NEWSWIRE) — Eularis today announced the release of a first-ever study on the ROI of named patient programmes (NPP), also known as compassionate use programs. The paper, ‘Implementing a pre-launch named patient programme – evidence of increased market share,’ provides pharmaceutical companies with insight and mathematical justification into the cash market share and revenue impact of pre-launch NPPs on brands, while outlining the benefits and challenges that they create.